Skip to main content
Equibles
EDSA logo

EDSA · Edesa Biotech, Inc.

Track EDSA — free

Use EDSA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.78 +0.05 (+0.95%) At close · Sep 1
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company’s ability to continue as a going concern is dependent on obtaining additional funding through financings, other strategic activities as well as via grants, to fund the development of its drug candidates. There can be no assurance that the Company will be successful in raising the necessary financing. These conditions indicate the existence of a material uncertainty that may cast substantial doubt about the Company’s ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$44.45M
Shares
9.64M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.78 Open$4.78 Day$4.61–5.01 52W close$0.80–18.28 Avg vol 30d86K Short int209K · 2.2% float · 5.9d Short vol62% Last earningsFeb 16, 2021 DataOct 2023–Sep 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Oct 11, 2023; bars on opposite sides are not compared.

Up next

FQ4-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.67
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −9%
below
Price vs 50-day avg −20%
below
RSI (14) 42
neutral
MACD trend Positive
52-week position 23%
mid-range
Momentum
relative strength
Weak
1-month return −11%
trailing
6-month return −28%
trailing
YTD return +237%
this year
Relative strength −40%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+18% holders QoQ · +11 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.17% of float · ▼ -3.4% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
33 holders — near 3-yr high, broad support
Squeeze score 50
elevated · 0–100
Fundamentals
Poor
Revenue growth −100%
Y/Y
EPS growth −58%
Y/Y
Free cash flow $-7.3M
Quant / Vol
risk profile
Very High
Volatility 194%
annualized · 1-yr
Max drawdown −76%
past year
ATR 12.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−9% Bearish
Price vs 50-day avg
−20% Bearish
RSI (14)
42 Neutral
MACD trend
Positive Bullish
52-week position
23% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+18% holders QoQ · +11 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.17% of float · ▼ -3.4% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
33 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $5 · 23% Range high $18
vs 200-day avg -9% vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EDSA
Edesa Biotech, Inc.
this stock
$44.45M +236.6% -100.0% — 2.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +20.8% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.77B +6.7% +20.8% 19.7 2.3%
ARGX
Argenx SE
 $64.16B +22.3% — — 1.9%
MRNA
Moderna, Inc.
 $61.59B +423.1% +4.3% — 13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
33
% held
38.9%
Net QoQ
+1.1M sh
Top holder
Velan Capital Investment…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Falling
Shares short
209.0K
Days to cover
5.9d
Change
-7.4K sh
View
Short Volume
Short vol %
62%
As of
Sep 1, 2026
Short Total
View
Fails to Deliver
FTD shares
345
Value
$1.9K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
38.0%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-7.2M
EPS diluted
$-3.99
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 20, 2026
This year
13
View
Exempt Offerings
Offering
$3.5M
Filed
Jun 26, 2026
View
Earnings & Events
Earnings Calls
Last call
Feb 16, 2021
View

Performance

Raw-price comparisons begin at the captured split on Oct 11, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
EDSA +7.4% -10.8% -27.8% +1.0% +236.6%
SPY -0.5% -1.2% +12.6% -0.7% +11.7%
vs SPY +8.0% -9.6% -40.4% +1.6% +224.9%
Key facts CIK 1540159 CUSIP 27966L306 13F (30d) 32 filings 30 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)